Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor-Positive, ERBB2-Negative Breast Cancer Treatment

JAMA Netw Open. 2022 Apr 1;5(4):e224380. doi: 10.1001/jamanetworkopen.2022.4380.

Authors

Yehoda M Martei^{1

2}, Amy S Clark^{1

2}

Affiliations

¹ Department of Medicine (Hematology-Oncology), Perelman School of Medicine of the University of Pennsylvania, Philadelphia.
² Abramson Cancer Center, University of Pennsylvania, Philadelphia.

PMID: 35416996
DOI: 10.1001/jamanetworkopen.2022.4380

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Female
Humans
Receptor, ErbB-2

Substances

ERBB2 protein, human
Receptor, ErbB-2